The Medical Advisor

An evidence-based overview of Dimethyl Sulfoxide (DMSO), its clinical history, safety profile, and therapeutic applications across multiple medical disciplines. Introduction: The Forgotten Side of Medicine Dimethyl sulfoxide (DMSO) is a simple chemical compound that has demonstrated remarkable efficacy in treating a wide variety of challenging health conditions. Upon its initial discovery, DMSO rapidly gained traction across the United States, backed by compelling clinical data and overwhelming public support. Despite heavy investments from pharmaceutical companies, endorsements from professional athletes, and over 10,000 articles on its biological implications and 30,000 articles on its chemistry in the scientific literature over the past 40 years, DMSO remains largely unknown to the general public today. Due to historical political friction and regulatory hurdles spanning decades, it was sidelined and frequently mischaracterized as dangerous. Howeve...

An evidence-based review of Dimethyl Sulfoxide (DMSO) as a safe, highly effective alternative to standard painkillers and its broad applications in modern clinical practice. The Crisis of Standard Pain Management For decades, the standard of care for treating pain and musculoskeletal injuries has relied heavily on Nonsteroidal Anti-inflammatory Drugs (NSAIDs like ibuprofen) and, in severe cases, opioids. Unfortunately, these conventional treatments come with catastrophic safety profiles. Both NSAIDs and opioids are responsible for tens of thousands of deaths annually, and NSAIDs remain the leading cause of drug-induced hospital admissions due to severe gastrointestinal and renal toxicity. In stark contrast, Dimethyl Sulfoxide (DMSO)—a simple, naturally occurring compound—has been used by millions of people over the last 60 years without a single recorded death. A meticulous human toxicology study demonstrated that taking DMSO for 90 days at 3 to 30 times the sta...

Abstract Background: Drug repurposing has emerged as a strategy in oncology to identify low-cost, widely available agents with potential anticancer activity. Antiparasitic benzimidazoles (fenbendazole, mebendazole) and the macrocyclic lactone ivermectin have been proposed as adjunctive therapies in breast cancer based on preclinical mechanistic data and anecdotal clinical reports. Interest has grown within integrative oncology communities, particularly for advanced or treatment-resistant disease. Objective: To compile and summarize reported case experiences describing the use of fenbendazole, ivermectin, and mebendazole in patients with breast cancer, and to outline proposed biological mechanisms and current evidence gaps. Methods: Publicly available case reports, patient testimonials, and practitioner-shared clinical narratives involving breast cancer patients who used fenbendazole, ivermectin, or mebendazole were reviewed and categorized by disease stage, concurrent conventiona...